文献速递胰腺与胆道疾病消化道肿瘤与早癌消化内镜

胆汁中的细胞外囊泡作为恶性胆管狭窄的标志物

Extracellular Vesicles in Bile as Markers of Malignant Biliary Stenoses.
PubMed 文献 · Gastroenterology · 2017-05-04

研究收集50例胆总管狭窄患者的胆汁和血液,用纳米颗粒追踪分析测定细胞外囊泡浓度,发现胆汁中细胞外囊泡浓度可区分恶性与非恶性胆总管狭窄,验证队列中阈值9.46×10^14个/升的准确率达100%,血清细胞外囊泡诊断准确率为63.3%。

要点

  • 胆汁细胞外囊泡浓度在恶性胆总管狭窄患者中显著高于对照组或非恶性狭窄患者。
  • 胆汁细胞外囊泡阈值9.46×10^14个/升在验证队列中以100%准确率区分恶性与非恶性胆总管狭窄。
  • 血清细胞外囊泡区分恶性与非恶性胆总管狭窄的诊断准确率为63.3%。

核心结论

  • 胆汁样本中细胞外囊泡浓度以100%准确率区分恶性与非恶性胆总管狭窄。
  • 需要进一步研究来证实这些发现。

研究设计与样本

  • 研究纳入50例在欧洲大学医院接受治疗性内镜逆行胰胆管造影的胆总管狭窄患者,收集胆汁和血液样本。
  • 恶性狭窄组包括胰腺癌20例和胆管癌5例,非恶性狭窄组为慢性胰腺炎15例,另纳入10例胆道结石所致胆总管梗阻患者作为对照。
  • 发现队列由前10例经组织分析诊断为胰腺癌的患者和10例连续对照组成,用于确定胆汁细胞外囊泡的最佳鉴别阈值。
  • 验证队列由30例连续患者组成,其中恶性(胰腺癌或胆管癌)15例、非恶性(慢性胰腺炎)15例,用于验证胆汁细胞外囊泡浓度的诊断性能。
  • 细胞外囊泡浓度通过纳米颗粒追踪分析测定,采用Mann-Whitney检验和非参数Spearman相关分析比较样本,用受试者工作特征曲线下面积确定诊断准确性。

主要发现

  • 在发现队列中,恶性胆总管狭窄患者胆汁细胞外囊泡中位浓度为2.41×10^15个/升,显著高于对照组或非恶性狭窄患者的1.60×10^14个/升(P < .0001)。
  • 在验证队列中,恶性胆总管狭窄患者胆汁细胞外囊泡中位浓度为4.00×10^15个/升,显著高于非恶性狭窄患者的1.26×10^14个/升(P < .0001)。
  • 胆汁细胞外囊泡阈值9.46×10^14个/升在发现队列中最佳区分恶性胆总管狭窄患者与对照。
  • 在验证队列中,该阈值以100%准确率区分恶性与非恶性胆总管狭窄。
  • 血清细胞外囊泡浓度区分恶性与非恶性胆总管狭窄患者的诊断准确率为63.3%。

关键数值与推荐

  • 胆汁细胞外囊泡鉴别阈值为9.46×10^14个/升。
  • 发现队列中恶性组胆汁细胞外囊泡中位浓度2.41×10^15个/升 vs 对照组或非恶性组1.60×10^14个/升(P < .0001)。
  • 验证队列中恶性组胆汁细胞外囊泡中位浓度4.00×10^15个/升 vs 非恶性组1.26×10^14个/升(P < .0001)。
  • 血清细胞外囊泡诊断准确率为63.3%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 需要进一步研究来证实这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Algorithms for diagnosis of malignant common bile duct (CBD) stenoses are complex and lack accuracy. Malignant tumors secrete large numbers of extracellular vesicles (EVs) into surrounding fluids; EVs might therefore serve as biomarkers for diagnosis. We investigated whether concentrations of EVs in bile could discriminate malignant from nonmalignant CBD stenoses. METHODS: We collected bile and blood samples from 50 patients undergoing therapeutic endoscopic retrograde cholangiopancreatography at university hospitals in Europe for CBD stenosis of malignant (pancreatic cancer, n = 20 or cholangiocarcinoma, n = 5) or nonmalignant (chronic pancreatitis [CP], n = 15) origin. Ten patients with CBD obstruction due to biliary stones were included as controls. EV concentrations in samples were determined by nanoparticle tracking analyses. The discovery cohort comprised the first 10 patients with a diagnosis of pancreatic cancer, based on tissue analysis, and 10 consecutive controls. Using samples from these subjects, we identified a threshold concentration of bile EVs that could best discriminate between patients with pancreatic cancer from controls. We verified the diagnostic performance of bile EV concentration by analyzing samples from the 30 consecutive patients with a diagnosis of malignant (pancreatic cancer or cholangiocarcinoma, n = 15) or nonmalignant (CP, n = 15) CBD stenosis. Samples were compared using the Mann-Whitney test and nonparametric Spearman correlation analysis. Receiver operating characteristic area under the curve was used to determine diagnostic accuracy. RESULTS: In both cohorts, the median concentration of EVs was significantly higher in bile samples from patients with malignant CBD stenoses than controls or nonmalignant CBD stenoses (2.41 × 1015 vs 1.60 × 1014 nanoparticles/L in the discovery cohort; P < .0001 and 4.00 × 1015 vs 1.26 × 1014 nanoparticles/L in the verification cohort; P < .0001). A threshold of 9.46 × 1014 nanoparticles/L in bile best distinguished patients with malignant CBD from controls in the discovery cohort. In the verification cohort, this threshold discriminated malignant from nonmalignant CBD stenoses with 100% accuracy. Serum concentration of EVs distinguished patients with malignant vs patients with nonmalignant CBD stenoses with 63.3% diagnostic accuracy. CONCLUSIONS: Concentration of EVs in bile samples discriminates between patients with malignant vs nonmalignant CBD stenosis with 100% accuracy. Further studies are needed to confirm these findings. Clinical Trial registration no: ISRCTN66835592.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Severino V, Dumonceau JM, Delhaye M, et al. Extracellular Vesicles in Bile as Markers of Malignant Biliary Stenoses. Gastroenterology. 2017. PMID: 28479376. doi:10.1053/j.gastro.2017.04.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。